中药灌肠治疗慢性肾脏病的研究进展

doi:10.5246/jcps.2024.04.023

摘要/Abstract

摘要：

慢性肾脏病(CKD)作为一个公共卫生问题, 发病率高, 死亡率高, 寻找有效控制发展的治疗手段是亟待解决的难题。"肠-肾轴"理论的核心观点认为, 随着CKD的进展, 尿毒症毒素(UTs)逐渐蓄积, 肠道屏障功能受损, 肠道菌群失调; 反过来, 失调的肠道菌群和受损的肠道屏障通过加剧UTs的蓄积和诱导全身炎症反应等途径加重肾脏的损伤。基于此理论指导下的中药灌肠在治疗CKD上取得了一定的进展, 本文结合国内外相关文献对"肠-肾轴"理论和运用中药灌肠联合基础治疗、中药灌肠联合结肠透析和中药灌肠联合口服中药等进行综述, 以期为后续CKD的治疗提供新思路、新靶点。

关键词: 肠肾轴, 中药灌肠, 慢性肾脏病, 研究进展

Abstract:

Chronic kidney disease (CKD) has emerged as a pressing public health issue characterized by increasing incidence and mortality rates. The imperative for effective treatments to halt its progression cannot be overstated. Central to the concept of the "gut-kidney axis" is the belief that as CKD advances, uremic toxins (UTs) gradually build up, undermining the integrity of the intestinal barrier and resulting in an imbalanced gut microbiota. This dysbiosis in the gut microbiota, coupled with the compromised intestinal barriers, intensifies renal damage by furthering UT accumulation and inducing systemic inflammation. Grounded in this understanding, the use of Chinese herbal enemas has shown promising outcomes in CKD management. This review consolidates both domestic and international studies related to the "gut-kidney axis" and delves into the combination of Chinese herbal enemas with standard therapy, colon dialysis, and traditional oral Chinese medicine practices. Our aim is to shed light on novel perspectives and pinpoint emerging avenues for the evolving therapeutic landscape of CKD.

Key words: Gut-kidney axis, Chinese herbal enema, Chronic kidney disease, Research progress

Supporting:

桑永浩, 贠捷, 代丽娟, 宋立群. 中药灌肠治疗慢性肾脏病的研究进展[J]. 中国药学(英文版), 2024, 33(4): 305-315.

Yonghao Sang, Jie Yun, Lijuan Dai, Liqun Song. Chinese herbal enema therapy for the treatment of chronic kidney disease[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(4): 305-315.

参考文献 58

[1]	Webster, A.C.; Nagler, E.V.; Morton, R.L.; Masson, P. Chronic kidney disease. . Lancet. 2017, 389, 1238–1252.
[2]	Wilson, S.; Mone, P.; Jankauskas, S.S.; Gambardella, J.; Santulli, G. Chronic kidney disease: definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. J. Clin. Hypertens. 2021, 23, 831–834.
[3]	Crews, D.C.; Bello, A.K.; Saadi, G.; Li, P.K.T.; Garcia-Garcia, G.; Andreoli, S.; Crews, D.; Kalantar-Zadeh, K.; Kernahan, C.; Kumaraswami, L.; Saadi, G.; Strani, L. C. Burden, access, and disparities in kidney disease. J. Nephrol. 2019, 32, 1–8.
[4]	Jager, K.J.; Fraser, S.D.S. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol. Dial. Transplant. 2017, 32, ii121–ii128.
[5]	Lv, J.C.; Zhang, L.X. Prevalence and disease burden of chronic kidney disease. Adv. Exp. Med. Biol. 2019, 1165, 3–15.
[6]	Zhang, L.X.; Wang, F.; Wang, L.; Wang, W.K.; Liu, B.C.; Liu, J.; Chen, M.H.; He, Q.; Liao, Y.H.; Yu, X.Q.; Chen, N.; Zhang, J.E.; Hu, Z.; Liu, F.Y.; Hong, D.Q.; Ma, L.J.; Liu, H.; Zhou, X.L.; Chen, J.H.; Pan, L.; Wang, H.Y. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012, 379, 815–822.
[7]	Zhang, L.X.; Wang, H.B.; Long, J.Y.; Shi, Y.; Bai, K.H.; Jiang, W.S.; He, X.X.; Zhou, Z.Y.; Wang, J.W.; Wang, F.; Huang, J.F.; Zhao, M.H. China kidney disease network (CK-NET) 2014 annual data report. Am. J. Kidney Dis. 2017, 69, A4.
[8]	Jha, V.; Wang, A.Y.M.; Wang, H.Y. The impact of CKD identification in large countries: the burden of illness. Nephrol. Dial. Transplant. 2012, 27, iii32–iii38.
[9]	Zhang, L.X.; Wang, H.Y. Chronic kidney disease epidemic: cost and health care implications in China. Semin. Nephrol. 2009, 29, 483–486.
[10]	Coresh, J.; Astor, B.C.; Greene, T.; Eknoyan, G.; Levey, A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am. J. Kidney Dis. 2003, 41, 1–12.
[11]	Coresh, J.; Selvin, E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. JAMA. 2007, 298, 2038–2047.
[12]	Foreman, K.J.; Marquez, N.; Dolgert, A.; Fukutaki, K.; Fullman, N.; McGaughey, M.; Pletcher, M.A.; Smith, A.E.; Tang, K.; Yuan, C.W.; Brown, J.C.; Friedman, J.; He, J.W.; Heuton, K.R.; Holmberg, M.; Patel, D.J.; Reidy, P.; Carter, A.; Cercy, K.; Chapin, A.; Douwes-Schultz, D.; Frank, T.; Goettsch, F.; Liu, P.Y.; Nandakumar, V.; Reitsma, M.B.; Reuter, V.; Sadat, N.; Sorensen, R.J.D.; Srinivasan, V.; Updike, R.L.; York, H.; Lopez, A.D.; Lozano, R.; Lim, S.S.; Mokdad, A.H.; Vollset, S.E.; Murray, C.J.L. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018, 392, 2052–2090.
[13]	Meijers, B.K.I.; Evenepoel, P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol. Dial. Transplant. 2011, 26, 759–761.
[14]	Lu, P.H.; Yu, M.C.; Wei, M.J.; Kuo, K.L. The therapeutic strategies for uremic toxins control in chronic kidney disease. Toxins. 2021, 13, 573.
[15]	Young, V.B. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017, 356, j831.
[16]	Wu, I.W.; Lin, C.Y.; Chang, L.C.; Lee, C.C.; Chiu, C.Y.; Hsu, H.J.; Sun, C.Y.; Chen, Y.C.; Kuo, Y.L.; Yang, C.W.; Gao, S.S.; Hsieh, W.P.; Chung, W.H.; Lai, H.C.; Su, S.C. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int. J. Biol. Sci. 2020, 16, 420–434.
[17]	Pflughoeft, K.J.; Versalovic, J. Human microbiome in health and disease. Annu. Rev. Pathol. Mech. Dis. 2012, 7, 99–122.
[18]	Pahl, M.V.; Vaziri, N.D. The chronic kidney disease-colonic axis. Semin. Dial. 2015, 28, 459–463.
[19]	Runkle, E.A.; Mu, D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013, 337, 41–48.
[20]	Vaziri, N.D.; Yuan, J.; Rahimi, A.; Ni, Z.M.; Said, H.; Subramanian, V.S. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol. Dial. Transplant. 2012, 27, 2686–2693.
[21]	Vaziri, N.D.; Goshtasbi, N.; Yuan, J.; Jellbauer, S.; Moradi, H.; Raffatellu, M.; Kalantar-Zadeh, K. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am. J. Nephrol. 2012, 36, 438–443.
[22]	Vaziri, N.D.; Yuan, J.; Norris, K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am. J. Nephrol. 2013, 37, 1–6.
[23]	Vaziri, N.D.; Yuan, J.; Nazertehrani, S.; Ni, Z.M.; Liu, S.M. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am. J. Nephrol. 2013, 38, 99–103.
[24]	Xie, F.; Sun, S.; Xu, A.; Zheng, S.; Xue, M.; Wu, P.; Zeng, J.H.; Bai, L. Advanced oxidation protein products induce intestine epithelial cell death through a redox-dependent, c-Jun N-terminal kinase and poly (ADP-ribose) polymerase-1-mediated pathway. Cell Death Dis. 2014, 5, e1006.
[25]	Evenepoel, P.; Meijers, B.K.I.; Bammens, B.R.M.; Verbeke, K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. 2009, 76, S12–S19.
[26]	Tang, W.H.; Wang, Z.N.; Kennedy, D.J.; Wu, Y.P.; Buffa, J.A.; Agatisa-Boyle, B.; Li, X.S.; Levison, B.S.; Hazen, S.L. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015, 116, 448–455.
[27]	Lekawanvijit, S. Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities. Circ. J. 2015, 79, 2088–2097.
[28]	Huang, Y.H.; Zhou, J.; Wang, S.B.; Xiong, J.C.; Chen, Y.; Liu, Y.; Xiao, T.L.; Li, Y.; He, T.; Li, Y.; Bi, X.J.; Yang, K.; Han, W.H.; Qiao, Y.; Yu, Y.L.; Zhao, J.H. Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment. Theranostics. 2020, 10, 7384–7400.
[29]	Ritz, E. Intestinal-renal syndrome: mirage or reality? Blood Purif. 2011, 31, 70–76.
[30]	de Almeida Duarte, J.B.; de Aguilar-Nascimento, J.E.; Nascimento, M.; Nochi, R.J.Jr. Bacterial translocation in experimental uremia. Urol. Res. 2004, 32, 266–270.
[31]	Baumgart, D.C.; Dignass, A.U. Intestinal barrier function. Curr. Opin. Clin. Nutr. Metab. Care. 2002, 5, 685–694.
[32]	Rooks, M.G.; Garrett, W.S. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 2016, 16, 341–352.
[33]	Kim, S.M.; Song, I.H. The clinical impact of gut microbiota in chronic kidney disease. Korean J. Intern. Med. 2020, 35, 1305–1316.
[34]	Hsu, C.N.; Chang-Chien, G.P.; Lin, S.F.; Hou, C.Y.; Lu, P.C.; Tain, Y.L. Association of trimethylamine, trimethylamine N-oxide, and dimethylamine with cardiovascular risk in children with chronic kidney disease. J. Clin. Med. 2020, 9, 336.
[35]	Kanemitsu, Y.; Mishima, E.; Maekawa, M.; Matsumoto, Y.; Saigusa, D.; Yamaguchi, H.; Ogura, J.; Tsukamoto, H.; Tomioka, Y.; Abe, T.; Mano, N. Comprehensive and semi-quantitative analysis of carboxyl-containing metabolites related to gut microbiota on chronic kidney disease using 2-picolylamine isotopic labeling LC-MS/MS. Sci. Rep. 2019, 9, 19075.
[36]	Mishima, E.; Fukuda, S.; Mukawa, C.; Yuri, A.; Kanemitsu, Y.; Matsumoto, Y.; Akiyama, Y.; Fukuda, N.N.; Tsukamoto, H.; Asaji, K.; Shima, H.; Kikuchi, K.; Suzuki, C.; Suzuki, T.; Tomioka, Y.; Soga, T.; Ito, S.; Abe, T. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 2017, 92, 634–645.
[37]	Rysz, J.; Franczyk, B.; Ławiński, J.; Olszewski, R.; Ciałkowska-Rysz, A.; Gluba-Brzózka, A. The impact of CKD on uremic toxins and gut microbiota. Toxins. 2021, 13, 252.
[38]	Wong, J.; Piceno, Y.M.; DeSantis, T.Z.; Pahl, M.; Andersen, G.L.; Vaziri, N.D. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 2014, 39, 230–237.
[39]	Tian, S.C.; Xue, J.; Song, H.; Du, Q. Regulatory effects of traditional Chinese medicine on intestinal flora. J. Chin. Pharm. Sci. 2020, 29, 161–175.
[40]	Ma, Y.R.; Xin, M.Y.; Wu, J.L.; Wang, D.J.; Wang, H.; Wu, X.A. Changes in renal excretion pathways in rats with adenine-induced chronic renal failure. J. Chin. Pharm. Sci. 2021, 30, 319–333.
[41]	Rukavina Mikusic, N.L.; Kouyoumdzian, N.M.; Choi, M.R. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch. 2020, 472, 303–320.
[42]	Favero, C.; Carriazo, S.; Cuarental, L.; Fernandez-Prado, R.; Gomá-Garcés, E.; Perez-Gomez, M.V.; Ortiz, A.; Fernandez-Fernandez, B.; Sanchez-Niño, M.D. Phosphate, microbiota and CKD. Nutrients. 2021, 13, 1273.
[43]	Vaziri, N.D.; Wong, J.; Pahl, M.; Piceno, Y.M.; Yuan, J.; DeSantis, T.Z.; Ni, Z.M.; Nguyen, T.H.; Andersen, G.L. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013, 83, 308–315.
[44]	Wang, X.F.; Yang, S.T.; Li, S.H.; Zhao, L.; Hao, Y.L.; Qin, J.J.; Zhang, L.; Zhang, C.Y.; Bian, W.J.; Zuo, L.; Gao, X.; Zhu, B.L.; Lei, X.G.; Gu, Z.L.; Cui, W.; Xu, X.P.; Li, Z.M.; Zhu, B.Z.; Li, Y.; Chen, S.W.; Guo, H.Y.; Zhang, H.; Sun, J.; Zhang, M.; Hui, Y.; Zhang, X.L.; Liu, X.X.; Sun, B.W.; Wang, L.J.; Qiu, Q.L.; Zhang, Y.C.; Li, X.Q.; Liu, W.Q.; Xue, R.; Wu, H.; Shao, D.H.; Li, J.L.; Zhou, Y.J.; Li, S.C.; Yang, R.T.; Pedersen, O.B.; Yu, Z.Q.; Ehrlich, S.D.; Ren, F.Z. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020, 69, 2131–2142.
[45]	Nakabayashi, I.; Nakamura, M.; Kawakami, K.; Ohta, T.; Kato, I.; Uchida, K.; Yoshida, M. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol. Dial. Transplant. 2011, 26, 1094–1098.
[46]	Simenhoff, M.L.; Dunn, S.R.; Zollner, G.P.; Fitzpatrick, M.E.; Emery, S.M.; Sandine, W.E.; Ayres, J.W. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner. Electrolyte Metab. 1996, 22, 92–96.
[47]	Zou, C.; Lu, Z.Y.; Wu, Y.C.; Yang, L.H.; Su, G.B.; Jie, X.N.; Liu, X.S. Colon may provide new therapeutic targets for treatment of chronic kidney disease with Chinese medicine. Chin. J. Integr. Med. 2013, 19, 86–91.
[48]	Zeng, Y.Q.; Dai, Z.H.; Lu, F.H.; Lu, Z.Y.; Liu, X.S.; Chen, C.; Qu, P.H.; Li, D.C.; Hua, Z.S.; Qu, Y.N.; Zou, C. Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease. Oncotarget. 2016, 7, 17468–17478.
[49]	Ji, C.L.; Lu, F.H.; Wu, Y.C.; Lu, Z.Y.; Mo, Y.N.; Han, L.J.; Lin, Q.Z.; Liu, X.S.; Zou, C. Rhubarb enema increasing short-chain fatty acids that improves the intestinal barrier disruption in CKD may be related to the regulation of gut dysbiosis. BioMed Res. Int. 2022, 2022, 1896781.
[50]	Zou, C.; Wu, Y.C.; Lin, Q. Effects of Chinese herbal enema therapy combined basic treatment on BUN, SCr, UA, and IS in chronic renal failure patients. Chin. J. Integr. Tradit. West. Med. 2012, 9, 1192–1195.
[51]	Ji, C.L.; Li, Y.; Mo, Y.N.; Lu, Z.Y.; Lu, F.H.; Lin, Q.Z.; Liu, X.S.; Zou, C.; Wu, Y.C. Rhubarb enema decreases circulating trimethylamine N-oxide level and improves renal fibrosis accompanied with gut microbiota change in chronic kidney disease rats. Front. Pharmacol. 2021, 12, 780924.
[52]	Lei, Y.; Ru, X.; Chen, X.J. Clinical Efficacy of Self-made Chinese Herbal Enema in Treating Stage 3-4 Chronic Kidney Disease and Its Effect on Inflammatory Factor Levels. J. Hunan Normal. Univ (Medical Edition). 2022, 2, 195–198.
[53]	Chen, J.; Zheng, Y.; Liao, L.; Liu, W.; Guo, Y.; Duan, L.; Lu, J. Retention Enema of Reducing Toxin and Stasis for the Treatment of Renal Insufficiency in Toxin-Stasis Syndrome. Chin. J. Tradit. Chin. Med. 2021, 1, 171–175.
[54]	Ji, C.L.; Deng, Y.S.; Yang, A.C.; Lu, Z.Y.; Chen, Y.; Liu, X.S.; Han, L.J.; Zou, C.A. Rhubarb enema improved colon mucosal barrier injury in 5/6 nephrectomy rats may associate with gut microbiota modification. Front. Pharmacol. 2020, 11, 1092.
[55]	Zhang, Q.; Li, T.X.; Huang, X.Y.; Yan, P.; Shi, K.F.; Wang, X.; Hou, H.L. Influence of Traditional Chinese Medicine Colonic Dialysis on Intestinal Microecology in Patients with Dampness and Blood Stasis Syndrome of Chronic Kidney Disease Stage 3-4. Chin. J. Mod. Drug Appl. 2023, 5, 155–159.
[56]	Ding, B.M.; Liang, X.P.; Shen, Y.; Shi, W. Effects of Heluo Jiangzhuo Decoction Retention Enema Combined with Colon Dialysis on Micro-inflammatory State, Renal Function,and Serum Ferritin in Patients with Chronic Kidney Disease and Turbidity and Stagnation Disorder. Hebei J. Tradit. Chin. Med. 2019, 12, 1799–1804.
[57]	Zhou, S.Q.; Lu, L.J.; Liu, M.S.; Hu, J.C.; Liao, D.L. Treatment of 42 cases of stage 4 chronic kidney disease with spleen-kidney qi deficiency and damp-heat internal obstruction type using modified Banxia Xiexin Tang combined with traditional Chinese medicine enema. J. Fujian Univ. Tradit. Chin. Med. 2018, 6, 23–24, 27.
[58]	Guo, J.H.; Zhou, L.; Jiang, C.B.; Bao, X.X.; Sun, W. Clinical study of combined use of Yishen Qingli Formula and Heluo Xiezhuo Formula with traditional Chinese medicine enema in the treatment of 45 cases of stage 4 chronic kidney disease. J. Jiangsu Univ. Tradit. Chin. Med. 2019, 10, 39–41.